

# Dihydrocucurbitacin B Datasheet

4<sup>th</sup> Edition (Revised in July, 2016)

## [ Product Information ]

**Name:** Dihydrocucurbitacin B

**Catalog No.:** CFN92140

**Cas No.:** 13201-14-4


**Purity:** > 95%

**M.F:** C<sub>32</sub>H<sub>48</sub>O<sub>8</sub>

**M.W:** 560.7

**Physical Description:** Powder

**Synonyms:** (10 $\alpha$ )-25-(Acetyloxy)-2 $\beta$ ,16 $\alpha$ ,20-trihydroxy-9 $\beta$ -methyl-19-norlanost-5-ene-3,11,22-trione.



## [ Intended Use ]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

## [ Source ]

The rhizomes of *Hemsleya amabilis* Diels.

## [ Biological Activity or Inhibitors ]

Dihydrocucurbitacin B, a triterpene isolated from *Cayaponia tayuya* roots, it can inhibit the inflammatory reactions induced by oxazolone, dinitrofluorobenzene, and sheep red blood cells, reduce both the edema and cell infiltration on different models of delayed type hypersensitivity (DTH) in mice ; it also can inhibit the proliferation of phytohemagglutinin-stimulated human T lymphocytes (IC<sub>50</sub> = 1.48 microM), halte the cell cycle in the G(0) phase; suggest that dihydrocucurbitacin B curbs DTH reactions by inhibiting NFAT, which in turn suppresses the proliferation of the most relevant cells involved in DTH reactions, namely the T cells.<sup>[1]</sup>

Dihydrocucurbitacin B can reduce cell proliferation due to a decrease in the expression of cyclins, mainly cyclin-B1 and disruption of the actin cytoskeleton, arresting B16F10 cells in G2/M phase, suggests that it is effective against cancer.<sup>[2]</sup>

### **[ Solvent ]**

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

### **[ HPLC Method ]<sup>[3]</sup>**

Mobile phase: Acetonitrile- H<sub>2</sub>O= 40:60;

Flow rate: 1.2 ml/min;

Column temperature: Room Temperature;

The wave length of determination: 230 nm.

### **[ Storage ]**

2-8°C, Protected from air and light, refrigerate or freeze.

### **[ References ]**

[1]Escandell J M,Recio M C,Máñez S,*et al.**J.Pharmacol.Expe.Ther.*, 2007, 322(3):1261-8.

[2]Siqueira J M,Gazola A C,Farias M R,*et al.**CancerChemoth.Pharm.*, 2009, 64(3):529-38.

[3]Krepesky P B,Cervelin M D O,Porath D,*et al.* *Rev. Bras. Farmacogn.*, 2009, 19(3):715-9.

## **[ Contact ]**

**Address:**

S5-3 Building, No. 111, Dongfeng Rd.,  
Wuhan Economic and Technological Development Zone,  
Wuhan, Hubei 430056,  
China

**Email:** [info@chemfaces.com](mailto:info@chemfaces.com)

**Tel:** +86-27-84237783

**Fax:** +86-27-84254680

**Web:** [www.chemfaces.com](http://www.chemfaces.com)

**Tech Support:** [service@chemfaces.com](mailto:service@chemfaces.com)